

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Proietti M., Romiti G.F., Raparelli V., Diemberger I., Boriani G., Vecchia L.A.D., et al. (2022). Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients. AGEING RESEARCH REVIEWS, 79, 1-11 [10.1016/j.arr.2022.101652].

Availability:

This version is available at: <https://hdl.handle.net/11585/903509> since: 2022-11-17

Published:

DOI: <http://doi.org/10.1016/j.arr.2022.101652>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

Frailty Prevalence and Impact on Outcomes in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of 1,187,000 Patients

Running Title: Frailty in AF Patients

Marco Proietti^{1,2,3*} MD PhD, Giulio Francesco Romiti^{4*} MD,
Valeria Raparelli^{5,6,7} MD PhD, Igor Diemberger⁸ MD PhD, Giuseppe Boriani⁹ MD
PhD, Laura Adelaide Dalla Vecchia¹⁰ MD, Giuseppe Bellelli^{11,12} MD,
Emanuele Marzetti^{13,14} MD PhD, Gregory YH Lip^{3,15†} MD, Matteo Cesari^{1,2†} MD PhD

¹Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy; ²Department of Clinical Sciences and Community Health, University of Milan, Italy; ³Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; ⁴Department of Translational and Precision Medicine, Sapienza – University of Rome, Italy; ⁵Department of Translational Medicine, University of Ferrara, Italy; ⁶University Center for Studies on Gender Medicine, University of Ferrara, Italy; ⁷University of Alberta, Faculty of Nursing, Edmonton, Alberta, Canada; ⁸Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy; ⁹Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Italy; ¹⁰Department of Cardiology, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy; ¹¹School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ¹²Acute Geriatrics Unit, San Gerardo Hospital ASST Monza, Monza, Italy; ¹³Università Cattolica del Sacro Cuore, Department of Geriatrics and Orthopedics, Rome, Italy; ¹⁴Center for Geriatric Medicine (Ce.M.I.), Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, Rome, Italy; ¹⁵Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

*Equally contributing authors

†Joint senior authors

Corresponding Author

Marco Proietti MD PhD FESC FEHRA

Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri

Via Camaldoli 64, 20138, Milan, Italy

ORCID: 0000-0003-1452-2478

Twitter Handle: @MProiettiMD

e-mail: marco.proietti@unimi.it

ABSTRACT

Frailty is a clinical syndrome characterized by a reduced physiologic reserve, increased vulnerability to stressors and an increased risk of adverse outcomes. People with atrial fibrillation (AF) are often burdened by frailty due to biological, clinical, and social factors. The prevalence of frailty, its management and association with major outcomes in AF patients are still not well quantified. We systematically searched PubMed and EMBASE, from inception to September 13th, 2021, for studies reporting the prevalence of frailty in AF patients. The study was registered in PROSPERO (CRD42021235854). 33 studies were included in the systematic review (n=1,187,651 patients). The frailty pooled prevalence was 39.7% (95%CI=29.9%-50.5%, $I^2=100\%$), while meta-regression analyses showed it is influenced by age, history of stroke, and geographical location. Meta-regression analyses showed that OAC prescription was influenced by study-level mean age, baseline thromboembolic risk, and study setting. Frail AF patients were associated with a higher risk of all-cause death (OR=5.56, 95%CI=3.46-8.94), ischemic stroke (OR=1.59, 95%CI=1.00-2.52), and bleeding (OR=1.64, 95%CI=1.11-2.41), when compared to robust individuals. In this systematic review and meta-analysis, the prevalence of frailty was high in patients with AF. Frailty may influence the prognosis and management of AF patients, thus requiring person-tailored interventions in a holistic or integrated approach to AF care.

KEYWORDS: atrial fibrillation; frailty; epidemiology; mortality; stroke.

1. INTRODUCTION

Frailty is a clinical syndrome characterized by reduced physiologic reserve and increased vulnerability to stressors; it represents a risk factor for negative health-related outcomes, including dependency and death (Morley et al., 2013) and is highly prevalent in the general population (~15%) (Collard et al., 2012). Frailty is today considered a public health priority, and its complexity requires specific managing strategies (Cesari et al., 2016). The relevance of frailty is also recognized in cardiovascular medicine (Aprahamian et al., 2018; Ida et al., 2019).

Atrial fibrillation (AF) is a highly prevalent condition in older persons, often in association with multimorbidity which complicates its clinical management (Hindricks et al., 2021; Proietti et al., 2019). However, the prevalence of frailty and associated factors in people with AF, as well as the impact of frailty on AF management and outcomes are not completely understood (Proietti and Cesari, 2021; Wilkinson et al., 2019). While the prevalence of frailty ranges between 1.6% and 56%, various studies show an association between presence of frailty and risk of all-cause death, although the extent of the association varied across studies (Proietti and Cesari, 2021). Furthermore, the impact of frailty on other outcomes in AF patients (such as stroke and major bleeding) has not been clearly elucidated (Proietti and Cesari, 2021). Moreover, previous studies have shown that frailty may be associated with an underuse of oral anticoagulant (OAC), based on the inclusion of very few cohorts (He et al., 2022; Oqab et al., 2018).

The aims of this study were the following: i) to report the cumulative prevalence of frailty in patients with AF; ii) to examine the associations between frailty and AF-

1 associated risk factors and comorbidities; iii) to describe prescriptions of OAC drugs
2 in patients with AF and frailty; and iv) to analyse the impact of frailty on clinical
3 outcomes in AF patients.

4

5

2. METHODS

This systematic review was performed according to the 'Meta-analysis Of Observational Studies in Epidemiology' (MOOSE) guidelines (Stroup et al., 2000) and reported according to the 'Preferred Reporting Items for Systematic Reviews and Meta-Analyses' (PRISMA) guidelines (Page et al., 2021). The protocol was registered on the international prospective register of systematic reviews (PROSPERO), N. CRD42021235854.

2.1 Search Strategy

A systematic and comprehensive literature search was performed on MEDLINE (accessed through PubMed) and EMBASE databases, from inception to September 13th, 2021. Relevant key terms were combined in the search strategy, including 'frailty', 'frail' and 'atrial fibrillation'. The full search strategy is reported in detail in the Supplementary Materials (Table S1).

2.2 Studies Selection

All articles retrieved from the literature search were systematically, sequentially, and independently screened for eligibility by two authors (MP and GFR). Each article included after the first screening phase focused on titles and abstracts was then evaluated considering the full text. Disagreements were resolved by collegial discussion.

2.3 Inclusion and Exclusion Criteria

Studies reporting data about the evaluation of frailty, irrespective of the tool used for its assessment, in AF patients were included. On the other side, studies on highly

selected cohorts of patients with AF, articles not in English, conference abstracts, letters, comments, editorials, case reports, systematic reviews, and/or meta-analysis were excluded. In the case of two or more studies based on the same cohort of patients, the study with the highest number of patients, the most complete data and/or the most recently published was considered.

2.4 Data Extraction and Quality Assessment

Data from the studies included were independently extracted by two authors (MP and GFR), through a standardized electronic form. We also extracted data on sample size, numbers of patients with prefrailty and frailty, age, proportion of women, prevalence of several comorbidities (including hypertension, diabetes mellitus, coronary artery disease (CAD), previous cerebrovascular disease, chronic heart failure (CHF), peripheral vascular disease (PVD)), CHA₂DS₂-VASc score, Charlson Comorbidity Index (CCI), proportion of patients prescribed with OAC and type of OAC prescribed, for each included study when available. Additionally, we extracted data on clinical outcomes (i.e., all cause death, stroke, major bleeding) according to the presence of frailty, when available.

All the included studies were independently evaluated by two authors (MP and GFR) to assess the risk of bias. We evaluated the risk of bias separately for each outcome of the study. We evaluated the risk of bias for studies reporting frailty prevalence using a customized version of the Newcastle-Ottawa Scale (NOS) for cross-sectional studies. The NOS is composed of 5 items organized into three domains (i.e., Selection, Comparability, Outcome), with a maximum score of 5 points (Table S2). Studies with a score ≤ 3 were considered at high risk of bias. For studies reporting on

outcomes according to the presence of frailty, we evaluated the risk of bias using a customized version of the NOS for population-based studies,(Viswanathan et al., 2012) composed of 8 items and three domains (i.e., Selection, Comparability, Outcome), with a maximum score of 9 points (Table S3). Each study with a NOS ≤ 6 was considered as at high risk of bias.

2.5 Definition of Outcomes

Prevalence of pre-frailty and frailty were defined irrespective of the assessment tool used in each study. Cut-off values to define the presence of pre-frailty and frailty were established according to the original studies, considering the usual practice or the authors' classification. We also investigated the management of patients with AF according to the presence of frailty (i.e., rates and type of OAC drugs prescription). Further, we investigated the impact of frailty on the risks of all-cause death, stroke, and major bleeding.

2.6 Statistical Analysis

The prevalence of frailty reported in the included studies was pooled with a generalized linear mixed model (i.e., random intercept logistic regression model)(Stijnen et al., 2010). The number of patients prescribed with OAC, the number of events, and the total number of patients according to the frailty status were pooled and compared using random-effects models. For continuous outcomes, mean, standard deviation (SD), and total number in each group were pooled and compared with inverse variance method.

1 Pooled estimates were reported as Odds Ratios (OR) and 95% confidence intervals
2 (CI), or mean difference and 95% CI for continuous variables. The inconsistency index
3 (I^2) was calculated to measure heterogeneity, with low heterogeneity defined as an I^2
4 of <25%, moderate heterogeneity when I^2 falls between 25 and 75%, and high
5 heterogeneity when I^2 was >75%, as per previously pre-specified cut-offs.(Higgins et
6 al., 2003)

7
8 For each outcome, a sensitivity analysis was performed with a “leave-one-out”
9 approach, in which all studies are removed one at a time to analyse their influence
10 on the primary analysis. We also performed a sensitivity analysis for the prevalence
11 of frailty using the inverse variance method and two different transformations of the
12 prevalence (i.e., logit transformation and Freeman-Tukey double arcsine).

13
14 To account for potential sources of heterogeneity in the pooled prevalence of frailty
15 and OAC prescription, we performed several subgroup analyses, according to
16 relevant study-level characteristics. We also performed meta-regression analyses,
17 according to mean age, sex, geographic location, and comorbidities. Multivariable
18 meta-regressions were also performed with the variables significantly associated at
19 univariate level.

20
21 Publication bias was assessed for studies reporting outcomes according to the frailty
22 status, with the use of funnel plots, which were visually inspected for asymmetry.
23 Egger’s test was also performed. All the statistical analyses were performed using R
24 version 4.0.3 (R Core Team, 2021, Vienna, Austria).

3. RESULTS

Among 1,350 records identified from the literature search (333 from PubMed, 1017 from EMBASE), 33 studies (a total of 1,187,651 persons with AF) were eventually included (Table 1) after removal of duplicates, title and abstract screening, and full-text assessment [Figure S1]. Sixteen studies were conducted in Europe; 7 in Asia; 6 in North America; and 4 in other geographical regions, including multinational cohorts. Fifteen were observational single-centre studies; 9 were observational multicentre studies; 5 were based on electronic medical records; and 3 were population-based studies. Four studies enrolled only patients with AF and a high thromboembolic risk. Finally, 14 studies were conducted in a hospital-based setting; 10 in community-based setting; and 9 in other settings, including mixed and unclear settings.

As for the type of frailty assessment tool used in the original studies, 8 cohorts used the frailty index proposed by Rockwood and Mitnitski; 6 were based on the Edmonton frail scale; 5 on the clinical frailty scale (CFS); 4 on the frailty phenotype designed by Fried and colleagues; 3 on the FRAIL tool; 2 on a claim frailty index (CFI); 2 on the Tilburg frailty index (TFI); and 3 on other methods. Finally, 13 studies were found to be at high risk of bias for the prevalence of frailty, while 2 studies were at high risk of bias among those reporting clinical outcomes according to frailty (Table S4 and S5, respectively).

3.1 Prevalence of Frailty and Pre-Frailty in patients with AF

Based on 33 studies including 1,187,651 patients with AF, the prevalence of frailty was 39.7% (95%CI: 29.9-50.5%), with high heterogeneity between studies (Figure

1) The pre-specified leave-one-out analysis showed little to no influence of individual studies on pooled estimates or heterogeneity (Figure S2 in supplementary materials). Sensitivity analyses according to the inverse variance methods were largely consistent with the main analysis [Table S6].

Thirteen studies reported data on the prevalence of pre-frailty, with a pooled prevalence of 35.0% (95%CI: 26.1-45.1%), and a high heterogeneity between studies [Figure S3]. The pre-specified leave-one-out sensitivity analysis showed little influence of individual studies on pooled prevalence or heterogeneity [Figure S4].

The results of the subgroup analysis for the prevalence of frailty are reported in Figure 2. Significant interactions were found according to geographical location, tool used for the assessment of frailty, study design, and risk of bias. The prevalence of frailty was found to be higher in European-based cohorts, and in the studies that used CFS or TFI, while the lowest prevalence of frailty was observed in studies using the frailty phenotype. A higher proportion of patients with AF were found to be frail in observational single-centres studies, while a lower prevalence was reported in population-based studies, randomized controlled trials, and studies with low risk of bias. Finally, the prevalence of frailty was lower in studies conducted in community-based settings, and higher in studies from hospital settings. Heterogeneity was found to be high in most of the analyzed subgroups.

3.2 Univariate and Multivariable Meta-Regression Analysis

To explore the potential sources of heterogeneity in our estimates for the prevalence of frailty, we performed univariate and multivariable meta-regression analyses

1 according to several study-level characteristics. On univariate analyses, mean age,
2 geographical location, study setting, risk of bias, and proportion of patients with
3 hypertension or history of stroke were found significantly associated with frailty
4 (Table S7 in Supplementary Materials). Particularly, studies with higher mean age
5 and higher proportion of patients with history of cerebrovascular accidents showed
6 increased prevalence of frailty. Conversely, studies based on Asian cohorts, those
7 conducted in a community-based setting, and those at low risk of bias were
8 associated with a lower prevalence of frailty, consistent with the results of subgroup
9 analyses. A non-significant trend was also observed between prevalence of
10 hypertension and frailty. Figure 3 shows a graphical representation of the
11 relationship between mean age, proportion of patients with history of stroke, and
12 prevalence of frailty.

13
14 In a multivariable meta-regression analysis, including the study-level characteristics
15 that were significantly associated with the prevalence of frailty at univariate analysis,
16 a model including mean age, prevalence of history of stroke, geographical location,
17 study setting, and risk of bias explained a relevant proportion of the observed
18 heterogeneity ($R^2=67.7\%$, Table S7), although none of the variables was
19 independently associated with the prevalence of frailty in the final model.

21 *3.3 Comorbidities and Clinical Characteristics Associated with Frailty*

22 Overall, 13 studies reported data on clinical characteristics and comorbidities in frail
23 and robust patients. All studies reported data about sex; 12 reported information on
24 history of stroke; 11 on hypertension, diabetes or congestive heart failure (CHF); 10
25 studies reported data on mean age; 7 on CHA₂DS₂-VASc score; 6 on peripheral

vascular disease; and 4 on Charlson Comorbidity Index (CCI). Frailty was associated with female sex and with all the main investigated comorbidities [Figure S5, Panel A]. Frail patients were older and with higher CHA₂DS₂-VASc and CCI scores [Figure S5, panel B]. High heterogeneity was found for all comparisons.

3.4 OAC Prescription According to Frailty Status

To evaluate OAC prescription across different degrees of frailty, we compared the rates of OAC prescription among frail, pre-frail, and robust patients.

After excluding studies in which all patients were already receiving OAC, we identified 17 studies that reported the number of patients prescribed with OAC according to frailty status. We performed one primary comparison (frail vs. robust patients), and 3 additional comparisons (frail vs. pre-frail/robust, frail vs. pre-frail, and pre-frail vs. robust subjects) [Figure 4]. None of the analyses showed significant differences in OAC prescription across frailty status categories, although there was a trend towards lower OAC prescription in frail persons. High heterogeneity was observed for all the comparisons.

The results of the sensitivity analyses according to the leave-one-out approach are reported in Figure S6. The exclusion of the study by Jankowska-Polanska et al.(Jankowska-Polańska et al., 2020) showed a significant lower OAC prescription in frail vs. pre-frail/robust patients (OR 0.78, 95%CI 0.62-0.97) [Figure S6, Panel B], while the omission of the study of Pilotto et al.(Pilotto et al., 2016) showed a significant higher OAC prescription for pre-frail vs. robust subjects (OR 1.22, 95%CI 1.06-1.43) [Figure S6, Panel D]. No significant influence of individual studies was found for the other analyses.

1
2 We performed three subgroup analyses for our primary comparison (i.e., frail vs.
3 robust patients), according to study design, thromboembolic risk of patients enrolled,
4 and study setting [Figure S7]. We found significant interaction by study type and in
5 OAC prescription in frail vs. robust patients. Frail patients enrolled in observational
6 multicentre cohorts and in the studies based on electronic medical records were less
7 likely to be prescribed with OAC, while the opposite was found in the two population-
8 based studies included. Frail persons were 28% less prescribed with OAC in studies
9 that included patients irrespective of baseline thromboembolic risk (OR: 0.72,
10 95%CI: 0.54-0.97), while a trend towards higher rates of prescription was found in
11 cohorts that enrolled only patients with high thromboembolic risk. Finally, significant
12 differences were found across study settings, with a 48% less OAC prescription in
13 frail patients enrolled in hospital-based studies, compared with non-significant
14 differences between frail and robust patients in community-based studies and
15 studies conducted in other settings.

16
17 To identify other possible causes of between-studies variability, we also performed
18 meta-regression analyses. Among the study-level characteristics investigated, only
19 mean age was significantly and inversely associated with the probability of OAC
20 prescription in frail patients compared with non-frail individuals ($R^2=37.4\%$; Table S8
21 in supplementary materials); non-significant trends were also observed for study
22 setting, with lower OAC prescription in hospital-based studies. A graphical
23 representation of the relationship between mean age of the included studies and the
24 OR for OAC prescription in frail patients is reported in Figure S8. In frail patients ≥ 80
25 years OAC was significantly less prescribed.

1
2 Finally, we compared frail vs. non-frail patients for the probability of receiving Non-
3 Vitamin K Antagonist OACs (NOACs) when anticoagulation is prescribed. In the 7
4 studies that reported available data for the comparison (Gugganig et al., 2021; Gullón
5 et al., 2019; Mostaza et al., 2018; Saczynski et al., 2020; Sanghai et al., 2021;
6 Sławuta et al., 2020; Son et al., 2019), we did not find any difference in the
7 probability of NOACs prescription between frail and robust patients [Figure S9].
8

9 *3.5 Risk of Outcomes according to Frailty Status in patients with AF*

10 To analyse the impact of frailty on the risk of all-cause mortality, stroke, and
11 bleeding, we compared frail vs. robust patients. We also compared frail vs. pre-
12 frail/robust, frail vs. pre-frail, and pre-frail vs. robust patients.
13

14 In the main comparison, frail patients had an increased risk of all outcomes,
15 compared with robust patients, with a 5.6-fold higher risk of all-cause mortality, and
16 roughly 60% increased risk of stroke and bleeding [Figure 5, Panels A to C,
17 respectively]. Heterogeneity was high for all comparisons. Similar results were found
18 for all other comparisons, with a higher risk of all-cause mortality according to any
19 worse frailty status [Figure S10-S12]. A sensitivity analysis on the risk of all-cause
20 mortality according to the study setting did not show any difference according to
21 study in the community, hospital, and other mixed settings [Figure S13].
22

23 *3.6 Publication Bias*

24 Assessment of publication bias was performed only for the studies reporting
25 outcomes according to the frailty status. Due to the low number of studies available

1 for the comparison of pre-frail patients, we only assessed publication bias for frail vs.
2 robust and frail vs. pre-frail/robust comparisons. There was no significant publication
3 bias across the outcomes investigated [Figure S14].

4

4. DISCUSSION

In this systematic review and meta-analysis of 1,187,651 persons with AF, approximately 40% were frail, with confidence intervals pointing towards a range of prevalence from 30% to 50%. Frail patients were older, more often women, and with higher prevalence of comorbidities. Frail AF patients had also a higher overall burden of multimorbidity, as well as of thromboembolic risk, but we did not find significant differences in OAC prescription in frail or pre-frail persons. While a differential influence on OAC prescription was found according to the study design, we observed a significant impact of mean age, with frail older persons (i.e., age ≥ 80) being less likely prescribed. When considering general AF cohorts (i.e., excluding those cohorts enrolling only patients with high thromboembolic risk), frail patients had a 30% lower chance to receive an OAC compared to robust ones. Finally, frail patients were at higher risk of all major adverse outcomes, and frailty was positively associated with all-cause death

In the last 20 years, the issue of frailty has increasingly been raised by geriatricians, underlining the significant impact on patients and health services, clinical care and research (Cesari et al., 2016; Vellas et al., 2012). Recent estimates suggest that the worldwide prevalence of frailty is about 18%, with a prevalence of pre-frailty of about 45%, irrespective of clinical setting (O’Caoimh et al., 2021). While a significant link between AF and frailty has already been described (Proietti and Cesari, 2021), our paper provides a solid estimate of the prevalence of frailty in patients with AF, documenting that approximately 4 out of 10 patients with AF are frail and 35% are pre-frail. These findings indicate that up to 75% of patients with AF have some degree of frailty, in contrast to 63% in the general population (O’Caoimh et al., 2021).

1 Based on subgroup analyses, we identified an overall prevalence of frailty of 17% in
2 AF patients in the community, which is higher than previous estimates in general
3 community cohorts showing a 12% prevalence, irrespective of frailty tools(Collard et
4 al., 2012). Furthermore, there was a higher prevalence of frailty compared with pre-
5 frailty, different from what was previously reported in general population(O’Caoimh et
6 al., 2021). Our estimates, which on some extent can be considered even too high
7 (and influenced by the overall high mean age of patients included in this analysis),
8 are supported by similar projects exploring the prevalence of frailty in other
9 cardiovascular diseases(Denfeld et al., 2017; Liperoti et al., 2021; Palmer et al.,
10 2019). Indeed, in these studies the extent of frailty burden was reported up to 70% of
11 the patients included in the studies, even though the overall mean ages of the
12 patients included in those meta-analyses were lower than our(Denfeld et al., 2017;
13 Liperoti et al., 2021; Palmer et al., 2019). Moreover, data from the subgroup analysis
14 about frailty assessment tools (i.e., frailty phenotype reporting the lower prevalence)
15 showed that, when frailty is multidimensionally assessed and/or via a functional
16 approach, its prevalence tends to be significantly higher (O’Caoimh et al., 2021).

17
18 In AF, multimorbidity is associated with a higher burden of thromboembolic and
19 bleeding risks, under-prescription and lower quality of OAC treatment, and a higher
20 risk of all major AF-related negative outcomes(Jani et al., 2018; Proietti et al., 2021,
21 2019). While multimorbidity represents a significant health construct in influencing
22 patients’ lives and the natural history of disease, it does not adequately capture the
23 individual’s overall capacity and physiological reserve. The evaluation of frailty
24 provides a deeper insight into the entire spectrum of phenomena influencing patient
25 care(Cesari et al., 2016; Morley et al., 2013). While agreement exists regarding the

1 theoretical construct of frailty(Morley et al., 2013), a large number of tools are used
2 for its assessment (Proietti and Cesari, 2020). Of these, the frailty phenotype
3 evaluates the residual physiological reserve on the basis of the phenotypic
4 manifestation of different physical signs and symptoms(Fried et al., 2001), while the
5 frailty index provides an overall evaluation of health deficits(Mitnitski et al., 2001).

6
7 Prior studies have provided a limited analysis of the relationship between frailty and
8 OAC prescription as well as of the impact of frailty on major negative
9 outcomes(Proietti and Cesari, 2021; Villani et al., 2018; Wilkinson et al., 2019).

10 Hence, our work provides a solid estimate of the prevalence of frailty and pre-frailty
11 in patients with AF. The evidence that 3 out of 4 AF patients show a certain degree
12 of frailty - with almost half of them frail – has major implications for their
13 management. Indeed, in recent years there has been a shift towards a more holistic
14 or integrated approach to AF care. Given the role of multimorbidity in AF, the need
15 for a more comprehensive assessment, characterisation, and personalized
16 management of patients with AF has emerged(Bhat et al., 2021; Potpara et al.,
17 2020). This approach has been advocated in clinical guidelines(Hindricks et al.,
18 2021), promoting the ‘Atrial Fibrillation Better Care’ (ABC) pathway(Lip, 2017)
19 wherein adherence to such an approach is associated with a significant reduction of
20 major negative outcomes(Romiti et al., 2021b). Such an integrated care approach
21 has also been advocated for other chronic conditions(Field et al., 2021; Lip and
22 Ntaios, 2021).

23
24 Frailty in the general population has been associated with an increased risk of all-
25 cause death, regardless the assessment tool used(Chang and Lin, 2015; Kojima et

al., 2018). In the general population, the presence of frailty (according to the frailty phenotype) was associated with a 2-fold and 1.5-fold risk of all-cause death relative to robust and pre-frail persons, respectively(Chang and Lin, 2015). Our estimates provide evidence that frail patients with AF have up to a 5-fold higher risk of dying compared with robust ones and an almost 3-fold higher risk compared to those who are pre-frail. Furthermore, the risk of all-cause death was not significantly different according to the study setting, even though the low number of studies considered suggests caution in interpretation. In a recent study enrolling long-term care residents with AF, the presence of geriatric conditions (e.g., recent fall, functional dependency, cognitive impairment, mobility impairment) did not affect the risk of stroke or bleeding (Kapoor et al., 2022). In contrast, our findings indicate that frailty may influence the onset of adverse outcomes in AF patients.

In recent years several researchers put significant efforts in defining the concept of 'inflammageing', defined as a low-grade systemic inflammatory status contributing to the development of ageing-related diseases and conditions(Ferrucci and Fabbri, 2018; Franceschi et al., 2018). Such pro-inflammatory status has been associated to the development and perpetuation of frailty(Kanapuru and Ershler, 2009; Van Epps et al., 2016) which is associated with increased systemic inflammatory markers(Soysal et al., 2016). Similarly, inflammation has a significant role in initiating, determining and perpetuating AF(Boriani et al., 2021; Brundel et al., 2022; Korantzopoulos et al., 2018). From this perspective, even if not supported by specific data we can postulate that the increased inflammatory burden firstly ignites AF and subsequently, with other inflammatory stimuli related to AF itself, characterise AF along with the high burden of risk factors and multimorbidity which characterize

1 AF(Boriani et al., 2021), determines the occurrence of frailty. The epidemiological
2 evidence linking AF and frailty, which interplay could amplify the inflammatory state,
3 and the high risk of several relevant clinical events related to AF(Odutayo et al.,
4 2016), that become less manageable for a frail individual, can suggest the possible
5 mechanism entailing the higher risk of outcomes.

6
7 Hence, a formal evaluation of frailty should be conducted in every older person with
8 AF to aid personalized interventions. In patients with frailty, a comprehensive
9 geriatric assessment followed by a personalized intervention effectively reduces the
10 burden of frailty itself and provides a significant improvement in clinical
11 outcomes(Cesari et al., 2015; Ellis et al., 2017). A more formal assessment of frailty
12 to identify those in need of comprehensive geriatric assessment (and the consequent
13 personalization of care) could reduce the risk of negative outcomes.

14
15 Although we did not find a significant reduction in the overall population, the
16 presence of frailty can negatively affect the prescription of OAC, modulated by
17 increasing age, study setting, and baseline thromboembolic risk. This suggests that
18 chronological age may be considered more important than the biological age
19 (captured by frailty) in the clinical decision process (as observed in other
20 cohorts(Fumagalli et al., 2015; Marzona et al., 2019)). Conversely, in patients at high
21 thromboembolic risk, the increased clinical complexity (i.e., higher risk of outcomes)
22 related to frailty shows a trend towards higher OAC prescription. Indeed, the
23 differences we found - with observational studies characterized by lower prescription,
24 and population-based studies showing a higher rate of prescription - underline the
25 differential way to consider the presence of frailty. In observational studies, when

1 frailty is explicitly assessed, its presence may discourage OAC prescriptions, which
2 might relate to the fear of adverse events (i.e., major, or intracranial bleeding) or to
3 the assumption that OAC would be unable to substantially reduce the risk of adverse
4 events in frail patients. In population-based studies, the higher risk profile of frail
5 patients with AF might drive more OAC prescriptions. Regarding the prescription of
6 VKA and NOACs in frail patients, our data did not show any difference, highlighting
7 the limited evidence regarding the effectiveness and safety of NOACs in this specific
8 patient subgroup(Grymonprez et al., 2020). Notwithstanding, recent findings provide
9 reassuring data regarding the use of apixaban in patients with AF and frailty(Kim et
10 al., 2021; Lip et al., 2021). On the other side, there is currently limited data on the
11 efficacy of novel approach for thromboembolic risk preventions, such as left atrial
12 appendage occlusion, which may represent an interesting alternative for frail patients
13 who are deemed not candidate to OAC.(Volgman et al., 2022) Further studies are
14 needed to shed light on these perspectives.

15
16 Our work has important implications in terms of clinical and public health
17 implications. On the clinical point of view, the assessment of frailty and the
18 consequential personalization of offered care could reduce the burden of adverse
19 clinical events by allocating person-tailored interventions, in conjunction with an
20 integrated AF care approach. Benefits are not limited to the patient-level, but may
21 also positively impact the public health, given the costs associated to both
22 conditions(Burdett and Lip, 2020; Hoogendijk et al., 2019). Projecting our findings on
23 the growing prevalence and burden of AF, it might be conceivable to decentralize
24 services, privileging primary care models to traditional hospital-based ones. Indeed,
25 recommendations coming also from the World Health Organization support the

strengthening of primary care for the preventive, multidisciplinary, and integrated management of older persons, especially the most vulnerable ones(World Health Organisation, 2017). In this context, it is foreseeable the need to reorient primary care services to better allow them the management of patients with AF, in particular when frailty is simultaneously present(Cesari et al., 2016).

Lastly, we also advocate the need for specific studies which will test how the evaluation of frailty and the integrated care approach now recommended for AF patients could have a positive impact on clinical outcomes (Hindricks et al., 2021)(Chao et al., 2021).

4.1 Limitations and Strengths

The main limitation to this systematic review is the high heterogeneity reported in our pooled estimates. Furthermore, it is possible that some cohorts were not included, despite our best efforts to include any relevant study, due to not being captured by our search strategy.

Nonetheless, our paper has important strengths. First, we performed specific analyses to evaluate heterogeneity, including the multivariable meta-regression, which accounts for roughly 65% of the observed heterogeneity in the pooled estimate for frailty prevalence. Notwithstanding, high heterogeneity is a common concern in epidemiological meta-analyses exploring the prevalence of conditions which could vary consistently across studies and is nowadays largely accepted, when proper study of heterogeneity is performed(Colditz et al., 1995; Odutayo et al.,

2016; Romiti et al., 2021a). Second, we included 33 studies and over a million of AF patients, thus providing robust data for the estimates reported in this analysis.

5. CONCLUSIONS

In this systematic review and meta-analysis, the prevalence of frailty was high (approximately 40%, with 95% confidence intervals ranging between 30-50%) in patients with AF. Frailty influences the prognosis and management of AF patients, thus requiring person-tailored interventions in a holistic or integrated approach to AF care.

1 **ACKNOWLEDGMENTS**

2 None.

3

4 **FUNDING**

5 This research did not receive any specific grant from funding agencies in the public,
6 commercial, or not-for-profit sectors.

7

8 **COMPETING INTEREST**

9 ID reports minor speaker fees from Bayer and Boehringer Ingelheim; GB received
10 small speaker's fees from Medtronic, Boston, Boehringer Ingelheim, and Bayer;
11 GYHL has been consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and
12 Daiichi-Sankyo. No fees were directly received personally. All the other authors have
13 nothing to declare.

FIGURE LEGENDS

Graphical Abstract – Frailty in Atrial Fibrillation (Created with Biorender.com)

Legend: CI= Confidence Interval; OR= Odds Ratio.

Figure 1 – Prevalence of Frailty in patients with Atrial Fibrillation.

Legend: CI= Confidence Interval; GLMM= General Linear Mixed Model.

Figure 2 – Subgroup Analyses for the Prevalence of Frailty.

Legend: CFI= Claim Frailty Index; CFS= Clinical Frailty Scale; CI= Confidence Interval; GLMM= Generalised Linear Mixed Model; RCT= Randomised Controlled Trial; TFI= Tilburg Frailty Index.

Figure 3 – Univariable meta-regressions for the prevalence of Frailty according to study-level characteristics

Legend: Panel A: Mean Age; Panel B: Prevalence of History of Stroke

Figure 4 – OAC Prescription according to Frailty status

Legend: CI= Confidence Interval; OR= Odds Ratio.

Figure 5 – Risk of All-Cause Death, Stroke and Bleeding in Frail vs. Robust subjects.

Legend: Panel A: All-Cause Death; Panel B: Stroke; Panel C: Bleeding; CI= Confidence Interval; MH= Mantel-Haenszel; OR= Odds Ratio.

REFERENCES

- Annoni, G., Mazzola, P., 2016. Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: Can we improve the current prescription of anticoagulants? *J. Geriatr. Cardiol.* 13, 226–232.
<https://doi.org/10.11909/J.ISSN.1671-5411.2016.03.010>
- Aprahamian, I., Sassaki, E., dos Santos, M.F., Izicki, R., Pulgrossi, R.C., Biella, M.M., Borges, A.C.N., Sassaki, M.M., Torres, L.M., Fernandez, Í.S., Pião, O.A., Castro, P.L.M., Fontenele, P.A., Yassuda, M.S., 2018. Hypertension and frailty in older adults. *J. Clin. Hypertens.* 20, 186–192.
<https://doi.org/10.1111/jch.13135>
- Bhat, A., Khanna, S., Chen, H.H.L., Gupta, A., Gan, G.C.H., Denniss, A.R., Macintyre, C.R., Tan, T.C., 2021. Integrated Care in Atrial Fibrillation: A Road Map to the Future. *Circ. Cardiovasc. Qual. Outcomes* 14.
<https://doi.org/10.1161/CIRCOUTCOMES.120.007411>
- Bo, M., Li Puma, F., Badinella Martini, M., Falcone, Y., Iacovino, M., Grisoglio, E., Menditto, E., Fonte, G., Brunetti, E., Isaia, G.C., D'Ascenzo, F., Gaita, F., 2017. Effects of oral anticoagulant therapy in older medical in-patients with atrial fibrillation: a prospective cohort observational study. *Aging Clin. Exp. Res.* 29, 491–497. <https://doi.org/10.1007/s40520-016-0569-7>
- Boriani, G., Vitolo, M., Diemberger, I., Proietti, M., Valenti, A.C., Malavasi, V.L., Lip, G.Y.H., 2021. Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. *Cardiovasc. Res.* 117, 1–21. <https://doi.org/10.1093/cvr/cvab147>
- Brundel, B.J.J.M., Ai, X., Hills, M.T., Kuipers, M.F., Lip, G.Y.H., de Groot, N.M.S., 2022. Atrial fibrillation. *Nat. Rev. Dis. Prim.* 8, 21.

1 <https://doi.org/10.1038/s41572-022-00347-9>

2 Burdett, P., Lip, G.Y.H., 2020. Atrial Fibrillation in the United Kingdom: Predicting
3 Costs of an Emerging Epidemic Recognising and Forecasting the Cost Drivers
4 of Atrial Fibrillation-related costs. *Eur. Hear. J. - Qual. Care Clin. Outcomes*.
5 <https://doi.org/10.1093/ehjqcco/qcaa093>

6 Campitelli, M.A., Bronskill, S.E., Huang, A., MacLagan, L.C., Atzema, C.L., Hogan,
7 D.B., Lapane, K.L., Harris, D.A., Maxwell, C.J., 2021. Trends in Anticoagulant
8 Use at Nursing Home Admission and Variation by Frailty and Chronic Kidney
9 Disease Among Older Adults with Atrial Fibrillation. *Drugs Aging* 38, 611–623.
10 <https://doi.org/10.1007/s40266-021-00859-1>

11 Cesari, M., Prince, M., Thiyagarajan, J.A., De Carvalho, I.A., Bernabei, R., Chan, P.,
12 Gutierrez-Robledo, L.M., Michel, J.-P., Morley, J.E., Ong, P., Rodriguez Manas,
13 L., Sinclair, A., Won, C.W., Beard, J., Vellas, B., 2016. Frailty: An Emerging
14 Public Health Priority. *J. Am. Med. Dir. Assoc.* 17, 188–92.
15 <https://doi.org/10.1016/j.jamda.2015.12.016>

16 Cesari, M., Vellas, B., Hsu, F.C., Newman, A.B., Doss, H., King, A.C., Manini, T.M.,
17 Church, T., Gill, T.M., Miller, M.E., Pahor, M., 2015. A physical activity
18 intervention to treat the frailty syndrome in older persons - Results from the
19 LIFE-P study. *Journals Gerontol. - Ser. A Biol. Sci. Med. Sci.* 70, 216–222.
20 <https://doi.org/10.1093/gerona/glu099>

21 Chang, S.F., Lin, P.L., 2015. Frail phenotype and mortality prediction: A systematic
22 review and meta-analysis of prospective cohort studies. *Int. J. Nurs. Stud.* 52,
23 1362–1374. <https://doi.org/10.1016/j.ijnurstu.2015.04.005>

24 Chao, T.F., Joung, B., Takahashi, Y., Lim, T.W., Choi, E.K., Chan, Y.H., Guo, Y.,
25 Sriratanasathavorn, C., Oh, S., Okumura, K., Lip, G.Y.H., 2021. 2021 Focused

Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on
Stroke Prevention in Atrial Fibrillation: Executive Summary *. *Thromb. Haemost.*
122, 20–47. <https://doi.org/10.1055/s-0041-1739411>

Colditz, G.A., Burdick, E., Mosteller, F., 1995. Heterogeneity in meta-analysis of data
from epidemiologic studies: A commentary. *Am. J. Epidemiol.* 142, 371–382.
<https://doi.org/10.1093/oxfordjournals.aje.a117644>

Collard, R.M., Boter, H., Schoevers, R.A., Oude Voshaar, R.C., 2012. Prevalence of
Frailty in Community-Dwelling Older Persons: A Systematic Review. *J. Am.*
Geriatr. Soc. 60, 1487–1492. <https://doi.org/10.1111/j.1532-5415.2012.04054.x>

De Simone, V., Mugnolo, A., Zanutto, G., Morando, G., 2020. Direct oral
anticoagulants for patients aged over 80 years in nonvalvular atrial fibrillation:
the impact of frailty. *J. Cardiovasc. Med.* 21, 562–569.
<https://doi.org/10.2459/JCM.0000000000000986>

Denfeld, Q.E., Winters-Stone, K., Mudd, J.O., Gelow, J.M., Kurdi, S., Lee, C.S.,
2017. The prevalence of frailty in heart failure: A systematic review and meta-
analysis. *Int. J. Cardiol.* 236, 283–289.
<https://doi.org/10.1016/j.ijcard.2017.01.153>

Ellis, G., Gardner, M., Tsiachristas, A., Langhorne, P., Burke, O., Harwood, R.H.,
Conroy, S.P., Kircher, T., Somme, D., Saltvedt, I., Wald, H., O'Neill, D.,
Robinson, D., Shepperd, S., 2017. Comprehensive geriatric assessment for
older adults admitted to hospital. *Cochrane Database Syst. Rev.* 2017.
<https://doi.org/10.1002/14651858.CD006211.pub3>

Ferrucci, L., Fabbri, E., 2018. Inflammageing: chronic inflammation in ageing,
cardiovascular disease, and frailty. *Nat. Rev. Cardiol.* 15, 505–522.
<https://doi.org/10.1038/s41569-018-0064-2>

1 Field, M., Kuduvalli, M., Torella, F., McKay, V., Khalatbari, A., Lip, G.Y.H., 2021.
2 Integrated Care Systems and the Aortovascular Hub. *Thromb. Haemost.*
3 <https://doi.org/10.1055/a-1591-8033>

4 Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., Santoro, A., 2018.
5 Inflammaging: a new immune–metabolic viewpoint for age-related diseases.
6 *Nat. Rev. Endocrinol.* 14, 576–590. <https://doi.org/10.1038/s41574-018-0059-4>

7 Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J.,
8 Seeman, T., Tracy, R., Kop, W.J., Burke, G., McBurnie, M.A., 2001. Frailty in
9 Older Adults: Evidence for a Phenotype. *Journals Gerontol. Ser. A Biol. Sci.*
10 *Med. Sci.* 56, M146–M157. <https://doi.org/10.1093/gerona/56.3.m146>

11 Fumagalli, S., Said, S.A.M., Laroche, C., Gabbai, D., Marchionni, N., Boriani, G.,
12 Maggioni, A.P., Popescu, M.I., Rasmussen, L.H., Crijns, H., Lip, G.Y.H., 2015.
13 Age-Related Differences in Presentation, Treatment, and Outcome of Patients
14 With Atrial Fibrillation in Europe: The EORP-AF General Pilot Registry
15 (EURObservational Research Programme-Atrial Fibrillation). *JACC Clin*
16 *Electrophysiol* 1, 326–334. <https://doi.org/10.1016/j.jacep.2015.02.019>

17 Grymonprez, M., Steurbaut, S., De Backer, T.L., Petrovic, M., Lahousse, L., 2020.
18 Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial
19 Fibrillation: A Systematic Review and Meta-Analysis. *Front. Pharmacol.* 11.
20 <https://doi.org/10.3389/fphar.2020.583311>

21 Gugganig, R., Aeschbacher, S., Leong, D.P., Meyre, P., Blum, S., Coslovsky, M.,
22 Beer, J.H., Moschovitis, G., Müller, D., Anker, D., Rodondi, N., Stempfel, S.,
23 Mueller, C., Meyer-Zürn, C., Kühne, M., Conen, D., Osswald, S., 2021. Frailty to
24 predict unplanned hospitalization, stroke, bleeding, and death in atrial fibrillation.
25 *Eur. Hear. J. - Qual. Care Clin. Outcomes* 7, 42–51.

1 <https://doi.org/10.1093/ehjqcco/qcaa002>

2 Gullón, A., Formiga, F., Díez-Manglano, J., Mostaza, J.M., Cepeda, J.M., Pose, A.,

3 Castiella, J., Suárez-Fernández, C., 2019. Influence of frailty on anticoagulant

4 prescription and clinical outcomes after 1-year follow-up in hospitalised older

5 patients with atrial fibrillation. *Intern. Emerg. Med.* 14, 59–69.

6 <https://doi.org/10.1007/s11739-018-1938-3>

7 He, L., He, R., Huang, J., Zou, C., Fan, Y., 2022. Impact of frailty on all-cause

8 mortality and major bleeding in patients with atrial fibrillation: A meta-analysis.

9 *Ageing Res. Rev.* <https://doi.org/10.1016/j.arr.2021.101527>

10 Higgins, J.P.T., Thompson, S.G., Deeks, J.J., Altman, D.G., 2003. Measuring

11 inconsistency in meta-analyses. *Br. Med. J.*

12 <https://doi.org/10.1136/bmj.327.7414.557>

13 Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomström-Lundqvist,

14 C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P.E., Fauchier, L., Filippatos,

15 G., Kalman, J.M., La Meir, M., Lane, D.A., Lebeau, J.-P., Lettino, M., Lip,

16 G.Y.H., Pinto, F.J., Thomas, G.N., Valgimigli, M., Van Gelder, I.C., Van Putte,

17 B.P., Watkins, C.L., ESC Scientific Document Group, 2021. 2020 ESC

18 Guidelines for the diagnosis and management of atrial fibrillation developed in

19 collaboration with the European Association for Cardio-Thoracic Surgery

20 (EACTS). *Eur. Heart J.* 42, 373–498. <https://doi.org/10.1093/eurheartj/ehaa612>

21 Hohmann, C., Hohnloser, S.H., Jacob, J., Walker, J., Baldus, S., Pfister, R., 2019.

22 Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in

23 Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation.

24 *Thromb. Haemost.* 119, 971–980. <https://doi.org/10.1055/s-0039-1683422>

25 Hoogendijk, E.O., Afilalo, J., Ensrud, K.E., Kowal, P., Onder, G., Fried, L.P., 2019.

Frailty: implications for clinical practice and public health. *Lancet*.
[https://doi.org/10.1016/S0140-6736\(19\)31786-6](https://doi.org/10.1016/S0140-6736(19)31786-6)

Ida, S., Kaneko, R., Imataka, K., Murata, K., 2019. Relationship between frailty and mortality, hospitalization, and cardiovascular diseases in diabetes: A systematic review and meta-analysis. *Cardiovasc. Diabetol.* 18, 81.
<https://doi.org/10.1186/s12933-019-0885-2>

Induruwa, I., Evans, N.R., Aziz, A., Reddy, S., Khadjooi, K., Romero-Ortuno, R., 2017. Clinical frailty is independently associated with non-prescription of anticoagulants in older patients with atrial fibrillation. *Geriatr. Gerontol. Int.* 17, 2178–2183. <https://doi.org/10.1111/ggi.13058>

Jani, B.D., Nicholl, B.I., McQueenie, R., Connelly, D.T., Hanlon, P., Gallacher, K.I., Lee, D., Mair, F.S., 2018. Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort. *Europace* 20, f329–f336.
<https://doi.org/10.1093/europace/eux322>

Jankowska-Polańska, B., Polański, J., Dudek, K., Sławuta, A., Mazur, G., Gajek, J., 2020. The Role of Sleep Disturbance, Depression and Anxiety in Frail Patients with AF—Gender Differences. *J. Clin. Med.* 10, 11.
<https://doi.org/10.3390/jcm10010011>

Kanapuru, B., Ershler, W.B., 2009. Inflammation, Coagulation, and the Pathway to Frailty. *Am. J. Med.* 122, 605–613.
<https://doi.org/10.1016/j.amjmed.2009.01.030>

Kapoor, A., Patel, J., Chen, Z., Crawford, S., McManus, D., Gurwitz, J., Shireman, T.I., Zhang, N., 2022. Geriatric conditions do not predict stroke or bleeding in long-term care residents with atrial fibrillation. *J. Am. Geriatr. Soc.* 70, 1218–1227. <https://doi.org/10.1111/jgs.17605>

1 Kim, D.H., Pawar, A., Gagne, J.J., Bessette, L.G., Lee, H., Glynn, R.J.,
2 Schneeweiss, S., 2021. Frailty and Clinical Outcomes of Direct Oral
3 Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation. *Ann.*
4 *Intern. Med.* 174, 1214–1223. <https://doi.org/10.7326/m20-7141>

5 Kim, S., Yoon, S., Choi, J., Kang, M., Cho, Y., Oh, I.-Y., Kim, C.-H., Kim, K., 2017.
6 Clinical implication of frailty assessment in older patients with atrial fibrillation.
7 *Arch. Gerontol. Geriatr.* 70, 1–7. <https://doi.org/10.1016/j.archger.2016.12.001>

8 Koca, M., Yavuz, B.B., Tuna Doğrul, R., Çalışkan, H., Şengül Ayçiçek, G.,
9 Özsürekcı, C., Balcı, C., Eşme, M., Ünsal, P., Halil, M., Cankurtaran, M., 2020.
10 Impact of atrial fibrillation on frailty and functionality in older adults. *Irish J. Med.*
11 *Sci.* (1971 -) 189, 917–924. <https://doi.org/10.1007/s11845-020-02190-x>

12 Kojima, G., Iliffe, S., Walters, K., 2018. Frailty index as a predictor of mortality: A
13 systematic review and meta-analysis. *Age Ageing* 47, 193–200.
14 <https://doi.org/10.1093/ageing/afx162>

15 Korantzopoulos, P., Letsas, K.P., Tse, G., Fragakis, N., Goudis, C.A., Liu, T., 2018.
16 Inflammation and atrial fibrillation: A comprehensive review. *J. Arrhythmia* 34,
17 394–401. <https://doi.org/10.1002/joa3.12077>

18 Lefebvre, M.C.D., St-Onge, M., Glazer-Cavanagh, M., Bell, L., Kha Nguyen, J.N.,
19 Viet-Quoc Nguyen, P., Tannenbaum, C., 2015. The Effect of Bleeding Risk and
20 Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial
21 Fibrillation: The FRAIL-AF Study. *Can. J. Cardiol.* 32, 169–76.
22 <https://doi.org/10.1016/j.cjca.2015.05.012>

23 Lip, G.Y., Ntaios, G., 2021. Integrated Care for Stroke Management: Easy as ABC.
24 *Thromb. Haemost.* <https://doi.org/10.1055/a-1632-1777>

25 Lip, G.Y.H., 2017. The ABC pathway: an integrated approach to improve AF

management. *Nat. Rev. Cardiol.* 14, 627–628.
<https://doi.org/10.1038/nrcardio.2017.153>

Lip, G.Y.H., Keshishian, A. V., Kang, A.L., Dhamane, A.D., Luo, X., Li, X., Balachander, N., Rosenblatt, L., Mardekian, J., Pan, X., Di Fusco, M., Garcia Reeves, A.B., Yuce, H., Deitelzweig, S., 2021. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. *J. Intern. Med.* 289, 42–52.
<https://doi.org/10.1111/joim.13140>

Liperoti, R., Vetrano, D.L., Palmer, K., Targowski, T., Cipriani, M.C., Lo Monaco, M.R., Giovannini, S., Acampora, N., Villani, E.R., Bernabei, R., Onder, G., 2021. Association between frailty and ischemic heart disease: a systematic review and meta-analysis. *BMC Geriatr.* 21, 357. <https://doi.org/10.1186/s12877-021-02304-9>

Liu, J., Du, X., Li, M., Jia, Z., Lu, S., Chang, S., Tang, R., Bai, R., Dong, J., Lip, G.Y.H., Ma, C., 2020. Frailty and Anticoagulant Therapy in Patients Aged 65 Years or Older with Atrial Fibrillation. *Cardiovasc. Innov. Appl.* 4, 153–161.
<https://doi.org/10.15212/CVIA.2019.0562>

Madhavan, M., Holmes, D.N., Piccini, J.P., Ansell, J.E., Fonarow, G.C., Hylek, E.M., Kowey, P.R., Mahaffey, K.W., Thomas, L., Peterson, E.D., Chan, P., Allen, L.A., Gersh, B.J., 2019. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. *Am. Heart J.* 211, 77–89.
<https://doi.org/10.1016/j.ahj.2019.01.005>

Marzona, I., Proietti, M., Vannini, T., Tettamanti, M., Nobili, A., Medaglia, M., Bortolotti, A., Merlino, L., Roncaglioni, M.C., 2019. Sex-related differences in prevalence, treatment and outcomes in patients with atrial fibrillation. *Intern.*

1 Emerg. Med. <https://doi.org/10.1007/s11739-019-02134-z>

2 Mitnitski, A.B., Mogilner, A.J., Rockwood, K., 2001. Accumulation of deficits as a
3 proxy measure of aging. *ScientificWorldJournal*. 1, 323–336.
4 <https://doi.org/10.1100/tsw.2001.58>

5 Mlynarska, A., Mlynarski, R., Golba, K.S., 2017. Older age and a higher EHRA score
6 allow higher levels of frailty syndrome to be predicted in patients with atrial
7 fibrillation. *Aging Male* 20, 23–27.
8 <https://doi.org/10.1080/13685538.2016.1241761>

9 Morley, J.E., Vellas, B., van Kan, G.A., Anker, S.D., Bauer, J.M., Bernabei, R.,
10 Cesari, M., Chumlea, W.C., Doehner, W., Evans, J., Fried, L.P., Guralnik, J.M.,
11 Katz, P.R., Malmstrom, T.K., McCarter, R.J., Gutierrez Robledo, L.M.,
12 Rockwood, K., von Haehling, S., Vandewoude, M.F., Walston, J., 2013. Frailty
13 consensus: a call to action. *J. Am. Med. Dir. Assoc.* 14, 392–7.
14 <https://doi.org/10.1016/j.jamda.2013.03.022>

15 Mostaza, J.M., Jiménez, M.J.R., Laiglesia, F.J.R., Peromingo, J.A.D., Robles, M.B.,
16 Sierra, E.G., Bilbao, A.S., Suárez, C., 2018. Clinical characteristics and type of
17 antithrombotic treatment in a Spanish cohort of elderly patients with atrial
18 fibrillation according to dependency, frailty and cognitive impairment. *J. Geriatr.*
19 *Cardiol.* 15, 268–274. <https://doi.org/10.11909/j.issn.1671-5411.2018.04.004>

20 Nguyen, T.N., Cumming, R.G., Hilmer, S.N., 2016. Atrial fibrillation in older
21 inpatients: are there any differences in clinical characteristics and
22 pharmacological treatment between the frail and the non-frail? *Intern. Med. J.*
23 46, 86–95. <https://doi.org/10.1111/imj.12912>

24 O’Caoimh, R., Sezgin, D., O’Donovan, M.R., William Molloy, D., Clegg, A.,
25 Rockwood, K., Liew, A., 2021. Prevalence of frailty in 62 countries across the

world: A systematic review and meta-analysis of population-level studies. *Age Ageing* 50, 96–104. <https://doi.org/10.1093/ageing/afaa219>

Odutayo, A., Wong, C.X., Hsiao, A.J., Hopewell, S., Altman, D.G., Emdin, C.A., 2016. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ* 354, i4482. <https://doi.org/10.1136/bmj.i4482>

Ohta, M., Hayashi, K., Mori, Y., Sato, H., Noto, T., Kawahatsu, K., Mita, T., Kazuno, Y., Sasaki, S., Doi, T., Hirokami, M., Tanaka, S., Yuda, S., 2021. Impact of Frailty on Bleeding Events Related to Anticoagulation Therapy in Patients With Atrial Fibrillation. *Circ. J.* 85, 235–242. <https://doi.org/10.1253/circj.CJ-20-0373>

Oqab, Z., Pournazari, P., Sheldon, R.S., 2018. What is the impact of frailty on prescription of anticoagulation in elderly patients with atrial fibrillation? A systematic review and meta-analysis. *J. Atr. Fibrillation* 10, 1–5. <https://doi.org/10.4022/jafib.1870>

Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., Brennan, S.E., Chou, R., Glanville, J., Grimshaw, J.M., Hróbjartsson, A., Lalu, M.M., Li, T., Loder, E.W., Mayo-Wilson, E., McDonald, S., McGuinness, L.A., Stewart, L.A., Thomas, J., Tricco, A.C., Welch, V.A., Whiting, P., Moher, D., 2021. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*. <https://doi.org/10.1136/bmj.n71>

Palmer, K., Vetrano, D.L., Padua, L., Romano, V., Rivoiro, C., Scelfo, B., Marengoni, A., Bernabei, R., Onder, G., 2019. Frailty Syndromes in Persons With Cerebrovascular Disease: A Systematic Review and Meta-Analysis. *Front. Neurol.* 10. <https://doi.org/10.3389/fneur.2019.01255>

1 Perera, V., Bajorek, B. V, Matthews, S., Hilmer, S.N., 2009. The impact of frailty on
2 the utilisation of antithrombotic therapy in older patients with atrial fibrillation.
3 Age Ageing 38, 156–162. <https://doi.org/10.1093/ageing/afn293>

4 Pilotto, Alberto, Gallina, P., Copetti, M., Pilotto, Andrea, Marcato, F., Mello, A.M.,
5 Simonato, M., Logroscino, G., Padovani, A., Ferrucci, L., Panza, F., Cruz-
6 Jentoft, A., Daragjati, J., Maggi, S., Mattace-Raso, F., Paccalin, M., Polidori,
7 M.C., Fontana, A., Topinkova, E., Trifirò, G., Welmer, A.K., 2016. Warfarin
8 Treatment and All-Cause Mortality in Community-Dwelling Older Adults with
9 Atrial Fibrillation: A Retrospective Observational Study. J. Am. Geriatr. Soc. 64,
10 1416–1424. <https://doi.org/10.1111/jgs.14221>

11 Polidoro, A., Stefanelli, F., Ciacciarelli, M., Pacelli, A., Di Sanzo, D., Alessandri, C.,
12 2013. Frailty in patients affected by atrial fibrillation. Arch. Gerontol. Geriatr. 57,
13 325–327. <https://doi.org/10.1016/j.archger.2013.04.014>

14 Potpara, T.S., Lip, G.Y.H., Blomstrom-Lundqvist, C., Boriani, G., Van Gelder, I.C.,
15 Heidbuchel, H., Hindricks, G., Camm, A.J., 2020. The 4S-AF scheme (Stroke
16 Risk; Symptoms; Severity of Burden; Substrate): A novel approach to in-depth
17 characterization (rather than classification) of atrial fibrillation. Thromb.
18 Haemost. <https://doi.org/10.1055/s-0040-1716408>

19 Proietti, M., Cesari, M., 2021. Describing the relationship between atrial fibrillation
20 and frailty: Clinical implications and open research questions. Exp. Gerontol.
21 152, 111455. <https://doi.org/10.1016/j.exger.2021.111455>

22 Proietti, M., Cesari, M., 2020. Frailty: What Is It? Adv. Exp. Med. Biol. 1216, 1–7.
23 https://doi.org/10.1007/978-3-030-33330-0_1

24 Proietti, M., Esteve-Pastor, M.A., Rivera-Caravaca, J.M., Roldán, V., Roldán
25 Rabadán, I., Muñiz, J., Cequier, Á., Bertomeu-Martínez, V., Badimón, L.,

1 Anguita, M., Lip, G.Y.H., Marín, F., 2021. Relationship between multimorbidity
2 and outcomes in atrial fibrillation. *Exp. Gerontol.* 153, 111482.
3 <https://doi.org/10.1016/j.exger.2021.111482>

4 Proietti, M., Marzona, I., Vannini, T., Tettamanti, M., Fortino, I., Merlino, L., Basili, S.,
5 Mannucci, P.M., Boriani, G., Lip, G.Y.H., Roncaglioni, M.C., Nobili, A., 2019.
6 Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral
7 Anticoagulant Drug Use. *Mayo Clin. Proc.* 94, 2427–2436.
8 <https://doi.org/10.1016/j.mayocp.2019.06.012>

9 Romiti, G.F., Corica, B., Pipitone, E., Vitolo, M., Raparelli, V., Basili, S., Boriani, G.,
10 Harari, S., Lip, G.Y.H., Proietti, M., 2021a. Prevalence, management and impact
11 of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review
12 and meta-analysis of 4,200,000 patients. *Eur. Heart J.* 42, 3541–3554.
13 <https://doi.org/10.1093/eurheartj/ehab453>

14 Romiti, G.F., Pastori, D., Rivera-Caravaca, J.M., Ding, W.Y., Gue, Y.X., Menichelli,
15 D., Gumprecht, J., Koziele, M., Yang, P.S., Guo, Y., Lip, G.Y.H., Proietti, M.,
16 2021b. Adherence to the “Atrial Fibrillation Better Care” Pathway in Patients with
17 Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-
18 Analysis of 285,000 Patients. *Thromb. Haemost.* [https://doi.org/10.1055/a-1515-](https://doi.org/10.1055/a-1515-9630)
19 9630

20 Saczynski, J.S., Sanghai, S.R., Kiefe, C.I., Lessard, D., Marino, F., Waring, M.E.,
21 Parish, D., Helm, R., Sogade, F., Goldberg, R., Gurwitz, J., Wang, W., Mailhot,
22 T., Bamgbade, B., Barton, B., McManus, D.D., 2020. Geriatric Elements and
23 Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE-AF. *J.*
24 *Am. Geriatr. Soc.* 68, 147–154. <https://doi.org/10.1111/jgs.16178>

25 Sanghai, S.R., Liu, W., Wang, W., Rongali, S., Orkaby, A.R., Saczynski, J.S., Rose,

1 A.J., Kapoor, A., Li, W., Yu, H., McManus, D.D., 2021. Prevalence of Frailty and
2 Associations with Oral Anticoagulant Prescribing in Atrial Fibrillation. *J. Gen.*
3 *Intern. Med.* <https://doi.org/10.1007/s11606-021-06834-1>

4 Sławuta, A., Jacek, P., Mazur, G., Jankowska-Polańska, B., 2020. Quality of Life and
5 Frailty Syndrome in Patients with Atrial Fibrillation. *Clin. Interv. Aging* Volume
6 15, 783–795. <https://doi.org/10.2147/CIA.S248170>

7 Son, Y.-J., Lee, K., Kim, B.-H., 2019. Gender Differences in the Association between
8 Frailty, Cognitive Impairment, and Self-Care Behaviors Among Older Adults with
9 Atrial Fibrillation. *Int. J. Environ. Res. Public Health* 16, 2387.
10 <https://doi.org/10.3390/ijerph16132387>

11 Soysal, P., Stubbs, B., Lucato, P., Luchini, C., Solmi, M., Peluso, R., Sergi, G., Isik,
12 A.T., Manzato, E., Maggi, S., Maggio, M., Prina, A.M., Cosco, T.D., Wu, Y.T.,
13 Veronese, N., 2016. Inflammation and frailty in the elderly: A systematic review
14 and meta-analysis. *Ageing Res. Rev.* 31, 1–8.
15 <https://doi.org/10.1016/j.arr.2016.08.006>

16 Stijnen, T., Hamza, T.H., Özdemir, P., 2010. Random effects meta-analysis of event
17 outcome in the framework of the generalized linear mixed model with
18 applications in sparse data. *Stat. Med.* 29, 3046–3067.
19 <https://doi.org/10.1002/sim.4040>

20 Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D.,
21 Moher, D., Becker, B.J., Sipe, T.A., Thacker, S.B., 2000. Meta-analysis of
22 observational studies in epidemiology: A proposal for reporting. *J. Am. Med.*
23 *Assoc.* 283, 2008–2012. <https://doi.org/10.1001/jama.283.15.2008>

24 Uchmanowicz, I., Lomper, K., Gros, M., Kałużna-Oleksy, M., Jankowska, E.A.,
25 Rosińczuk, J., Cyrkot, T., Szczepanowski, R., 2020. Assessment of Frailty and

1 Occurrence of Anxiety and Depression in Elderly Patients with Atrial Fibrillation.
2 Clin. Interv. Aging Volume 15, 1151–1161. <https://doi.org/10.2147/CIA.S258634>
3 Van Epps, P., Oswald, D., Higgins, P.A., Hornick, T.R., Aung, H., Banks, R.E.,
4 Wilson, B.M., Burant, C., Gravenstein, S., Canaday, D.H., 2016. Frailty has a
5 stronger association with inflammation than age in older veterans. *Immun.*
6 *Ageing* 13, 27. <https://doi.org/10.1186/s12979-016-0082-z>
7 Vellas, B., Cestac, P., Morley, J.E., 2012. Editorial implementing frailty into clinical
8 practice: We cannot wait. *J. Nutr. Heal. Aging* 16, 599–600.
9 <https://doi.org/10.1007/s12603-012-0096-y>
10 Villani, E.R., Tummolo, A.M., Palmer, K., Gravina, E.M., Vetrano, D.L., Bernabei, R.,
11 Onder, G., Acampora, N., 2018. Frailty and atrial fibrillation: A systematic
12 review. *Eur. J. Intern. Med.* 56, 33–38.
13 <https://doi.org/10.1016/j.ejim.2018.04.018>
14 Viswanathan, M., Ansari, M., Berkman, N., Chang, S., Hartling, L., McPheeters, L.,
15 Santaguida, P., Shamliyan, T., Singh, K., Tsertsvadze, A., Treadwell, J., 2012.
16 Methods Guide for Comparative Effectiveness Reviews Assessing the Risk of
17 Bias of Individual Studies in Systematic Reviews of Health Care Interventions
18 12-EHC047-EF.
19 Volgman, A.S., Nair, G., Lyubarova, R., Merchant, F.M., Mason, P., Curtis, A.B.,
20 Wenger, N.K., Aggarwal, N.T., Kirkpatrick, J.N., Benjamin, E.J., 2022.
21 Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-
22 the-Art Review. *J. Am. Coll. Cardiol.* <https://doi.org/10.1016/j.jacc.2021.10.037>
23 Wilkinson, C., Clegg, A., Todd, O., Rockwood, K., Yadegarfar, M.E., Gale, C.P., Hall,
24 M., 2021. Atrial fibrillation and oral anticoagulation in older people with frailty: a
25 nationwide primary care electronic health records cohort study. *Age Ageing* 50,

772–779. <https://doi.org/10.1093/ageing/afaa265>

Wilkinson, C., Todd, O., Clegg, A., Gale, C.P., Hall, M., 2019. Management of atrial fibrillation for older people with frailty: A systematic review and meta-analysis. *Age Ageing* 48, 196–204. <https://doi.org/10.1093/ageing/afy180>

Wilkinson, C., Wu, J., Searle, S.D., Todd, O., Hall, M., Kunadian, V., Clegg, A., Rockwood, K., Gale, C.P., 2020. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. *BMC Med.* 18, 401. <https://doi.org/10.1186/s12916-020-01870-w>

Wojszel, Z.B., Magnuszewski, L., Swietek, M., Kasiukiewicz, A., Swietek, M.L., Zubrewicz, K., 2019. Frailty syndrome and functional correlates of atrial fibrillation in patients admitted to the geriatric ward. *Gerontol. Pol.* 27, 11–15.

World Health Organisation, 2017. Integrated Care for Older People: Guidelines on Community-Level Interventions to Manage Declines in Intrinsic Capacity. World Health Organization.

Yamamoto, T., Yamashita, K., Miyamae, K., Koyama, Y., Izumimoto, M., Kamimura, Y., Hayakawa, S., Mori, K., Yamada, T., Tomita, Y., Murohara, T., 2019. The influence of frailty under direct oral anticoagulant use in patients with atrial fibrillation. *Heart Asia* 11, e011212. <https://doi.org/10.1136/heartasia-2019-011212>

Yang, M.T., Wu, Y.W., Chan, D.C., Chien, M.Y., 2020. The relationship between atrial fibrillation and frailty in community-dwelling older adults. *Arch. Gerontol. Geriatr.* 90, 104103. <https://doi.org/10.1016/j.archger.2020.104103>

Yang, P.S., Sung, J.H., Jang, E., Yu, H.T., Kim, T.H., Lip, G.Y.H., Joung, B., 2020. Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: A nationwide cohort study. *J.*

1 Arrhythmia 36, 668–677. <https://doi.org/10.1002/joa3.12364>

2

3

1 Table 1 – Main Characteristics of the Studies Included in the Systematic Review

STUDY	YEAR	GEOGRAPHIC LOCATION	STUDY TYPE	SETTING	INCLUSION CRITERIA	FRAILTY ASSESSMENT	N	PREFRAIL	FRAIL	AGE (mean)	CHA ₂ DS ₂ -VASC (mean)	OAC (%)
Annoni (Annoni and Mazzola, 2016)	2016	Italy	Observational Single Centre	Hospital	AF ≥65 years	Robinson	403	115	231	84.6	N/A	N/A
Bo (Bo et al., 2017)	2017	Italy	Observational Multicentre	Hospital	AF ≥65 years	Groningen	452	N/A	341	81.6	N/A	49.8
Campitelli (Campitelli et al., 2021)	2021	Canada	Administrative Database	Other	AF ≥65 years	Frailty Index	36466	12985	17778	N/A	N/A	50.8
De Simone (De Simone et al., 2020)	2020	Italy	Observational Single Centre	Hospital	AF ≥80 years	Edmonton	731	N/A	300	85	N/A	100
Gugganig (Gugganig et al., 2021)	2021	Switzerland	Observational Multicentre	Other	AF ≥65 years	Frailty Index	2369	1436	252	73	3.5	90.4
Gullon (Gullón et al., 2019)	2019	Spain	Observational Multicentre	Hospital	AF ≥65 years	FRAIL	615	N/A	297	85.2	5.3	69.8
Hohmann (Hohmann et al., 2019)	2019	Germany	Administrative Database	Community	AF ≥18 years on OAC	CFI	70501	N/A	36267	74	3.7	100
Induruwa (Induruwa et al., 2017)	2017	UK	Observational Single Centre	Hospital	AF ≥75 years	CFS	419	N/A	282	85*	4*	48.7
Jankowska-Polanska (Jankowska-Polańska et al., 2020)	2021	Poland	Observational Single Centre	Other	AF ≥60 years	Edmonton	158	N/A	84	70.9	N/A	42.4
Kim (Kim et al., 2017)	2017	Korea	Observational Single Centre	Other	AF ≥65 years	Frailty Index	365	68	176	79.4	N/A	34.2
Koca (Koca et al., 2020)	2020	Turkey	Observational Single Centre	Community	AF ≥65 years	Fried	64	33	10	75.3	N/A	N/A

Lefebvre (Lefebvre et al., 2015)	2016	Canada	Observational Multicentre	Hospital	AF ≥80 years	CFS	682	N/A	558	86.4	N/A	69.6
Lip (Lip et al., 2021)	2021	US	Administrative Database	Community	AF ≥65 years on OAC	CFI	404798	N/A	150487	N/A	N/A	N/A
Liu (Liu et al., 2020)	2020	China	Observational Multicentre	Other	AF ≥65 years	CFS	500	N/A	201	75.2	4*	39.6
Madhavan (Madhavan et al., 2019)	2019	US	Observational Multicentre	Community	AF ≥18 years	Fried	9749	N/A	575	75*	4*	76.4
Mlynarska (Mlynarska et al., 2017)	2017	Poland	Observational Single Centre	Hospital	AF ≥60 years	TFI	132	N/A	79	72.7	4.3	N/A
Mostaza (Mostaza et al., 2018)	2018	Spain	Observational Multicentre	Other	AF ≥75 years on OAC	FRAIL	837	N/A	360	83	5	100
Nguyen (Nguyen et al., 2016)	2016	Australia	Observational Single Centre	Hospital	AF ≥65 years	Edmonton	302	N/A	161	84.7	4.6	51.3
Ohta (Ohta et al., 2021)	2021	Japan	Observational Single Centre	Hospital	AF on OAC	Fried	120	N/A	34	77.7	3.1	100
Perera (Perera et al., 2009)	2009	Australia	Observational Single Centre	Hospital	AF ≥70 years	Edmonton	220	N/A	140	82.7	N/A	40.1
Pilotto (Pilotto et al., 2016)	2016	Italy	Observational Multicentre	Community	AF ≥65 years	MPI	1827	634	488	84.4	3.8	43.7
Polidoro (Polidoro et al., 2013)	2013	Italy	Observational Single Centre	Hospital	AF	Frailty Index	70	N/A	62	79.3	N/A	N/A
Saczynski (Saczynski et al., 2020)	2020	US	Observational Multicentre	Community	AF ≥65 years with High TE Risk	Fried	1244	659	172	75.5	4*	85.5
Sanghai (Sanghai et al., 2021)	2021	US	Administrative Database	Other	AF w/ CHA ₂ DS ₂ -VASc ≥2	Frailty Index	308664	99185	109475	77.7	4.6	39.5
Slawuta (Slawuta et al., 2020)	2020	Poland	Observational Single Centre	Hospital	AF ≥60 years	Edmonton	158	16	84	70.4	N/A	100

Son (Son et al., 2019)	2019	Korea	Observational Single Centre	Community	AF ≥60 years on AT	FRAIL	298	143	53	72.1	N/A	63.8
Uchmanowicz (Uchmanowicz et al., 2020)	2020	Poland	Observational Single Centre	Hospital	AF ≥65 years w/out CI	TFI	100	N/A	67	70.3	N/A	N/A
Wilkinson (Wilkinson et al., 2020)	2020	Multinational	RCT	Other	AF ≥21 years	Frailty Index	20867	12326	4082	N/A	N/A	100
Wilkinson 2 (Wilkinson et al., 2021)	2020	UK	Population- Based	Community	AF ≥65 years	Frailty Index	61177	20352	34382	79.7	3.8	53.1
Wojszel (Wojszel et al., 2019)	2019	Poland	Observational Single Centre	Hospital	AF	CFS	98	N/A	65	84*	N/A	N/A
Yamamoto (Yamamoto et al., 2019)	2019	Japan	Administrative Database	Other	AF on NOACs	CFS	240	N/A	120	76.1	4*	100
Yang MT (M. T. Yang et al., 2020)	2020	Taiwan	Population- Based	Community	AF ≥65 years	Edmonton	38	N/A	2	73.5	N/A	N/A
Yang PS (P. S. Yang et al., 2020)	2020	Korea	Population- Based	Community	AF ≥18 years CHA ₂ DS ₂ -VASc ≥1	Frailty Index	262987	37341	4104	58*	1.8	100

1 **Legend:** *median values; AF= Atrial Fibrillation; CFI= Claim Frailty Index; CFS= Clinical Frailty Scale; CI= Cognitive Impairment;

2 MPI= Multidimensional Prognostic Index; N/A= Not Available; NOACs= Non-Vitamin K Antagonist Oral Anticoagulants; OAC= Oral

3 Anticoagulant; RCT= Randomised Controlled Trial; TFI= Tilburg Frailty Indicator; UK= United Kingdom; US= United States.

4

Frailty Prevalence and Impact on Outcomes in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of 1,187,000 Patients

Running Title: Frailty in AF Patients

Marco Proietti^{1,2,3*} MD PhD, Giulio Francesco Romiti^{4*} MD,
Valeria Raparelli^{5,6,7} MD PhD, Igor Diemberger⁸ MD PhD, Giuseppe Boriani⁹ MD
PhD, Laura Adelaide Dalla Vecchia¹⁰ MD, Giuseppe Bellelli^{11,12} MD,
Emanuele Marzetti^{13,14} MD PhD, Gregory YH Lip^{3,15†} MD, Matteo Cesari^{1,2†} MD PhD

¹Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy; ²Department of Clinical Sciences and Community Health, University of Milan, Italy; ³Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; ⁴Department of Translational and Precision Medicine, Sapienza – University of Rome, Italy; ⁵Department of Translational Medicine, University of Ferrara, Italy; ⁶University Center for Studies on Gender Medicine, University of Ferrara, Italy; ⁷University of Alberta, Faculty of Nursing, Edmonton, Alberta, Canada; ⁸Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy; ⁹Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Italy; ¹⁰Department of Cardiology, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy; ¹¹School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ¹²Acute Geriatrics Unit, San Gerardo Hospital ASST Monza, Monza, Italy; ¹³Università Cattolica del Sacro Cuore, Department of Geriatrics and Orthopedics, Rome, Italy; ¹⁴Center for Geriatric Medicine (Ce.M.I.), Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, Rome, Italy; ¹⁵Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

*Equally contributing authors

†Joint senior authors

Corresponding Author

Marco Proietti MD PhD FESC FEHRA

Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri

Via Camaldoli 64, 20138, Milan, Italy

ORCID: 0000-0003-1452-2478

Twitter Handle: @MProiettiMD

e-mail: marco.proietti@unimi.it